-
1 Comment
IQVIA Holdings Inc is currently in a long term uptrend where the price is trading 28.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
IQVIA Holdings Inc's total revenue rose by 13.9% to $3B since the same quarter in the previous year.
Its net income has increased by 643.8% to $119M since the same quarter in the previous year.
Finally, its free cash flow grew by 28.7% to $574M since the same quarter in the previous year.
Based on the above factors, IQVIA Holdings Inc gets an overall score of 5/5.
Industry | Diagnostics & Research |
---|---|
Sector | Healthcare |
ISIN | US46266C1053 |
CurrencyCode | EUR |
Exchange | F |
Target Price | 279.06 |
---|---|
PE Ratio | 34.54 |
Dividend Yield | 0.0% |
Beta | 1.41 |
Market Cap | 35B |
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for QTS.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024